Cytek Biosciences files Form 3 for legal officer

Cytek Biosciences, Inc. filed an initial Form 3 insider ownership report for Ilan Feuchtwang, who serves as Chief Legal Officer and Secretary.

Accepted by SEC EDGAR 06/30/2026 - 09:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Cytek Biosciences, Inc. filed an initial Form 3 insider ownership report for Ilan Feuchtwang, who serves as Chief Legal Officer and Secretary. The filing is an administrative disclosure of insider status and does not report any share purchases, sales, or other transactions.

Key Terms

Form 3, reporting insider, Chief Legal Officer

3 terms

Form 3 regulatory

"filed an initial Form 3 insider ownership report"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting insider regulatory

"establishes him as a reporting insider under SEC rules"

Chief Legal Officer financial

"Ilan Feuchtwang, who serves as Chief Legal Officer and Secretary"

A chief legal officer is a senior executive responsible for overseeing a company's legal matters, ensuring that its activities comply with laws and regulations. They act like a company's legal guide, helping to prevent legal problems and manage risks. For investors, understanding this role is important because it reflects how well a company manages legal risks that could impact its stability and reputation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Cytek Biosciences (CTKB) Form 3 for Ilan Feuchtwang show?

The Form 3 for Cytek Biosciences’ Chief Legal Officer, Ilan Feuchtwang, is an initial insider ownership report. It establishes him as a reporting insider under SEC rules but does not list any stock purchases, sales, or derivative transactions in the disclosed data.

Does the CTKB Form 3 filing report any insider buying or selling?

No insider buying or selling is reported in this Cytek Biosciences Form 3. The transaction section is empty and summary counts show zero buys, zero sells, zero exercises, and no other dispositions, indicating no reportable transactions in this filing snapshot.

Who is the reporting person in the Cytek Biosciences (CTKB) Form 3?

The reporting person is Ilan Feuchtwang, identified as Chief Legal Officer and Secretary of Cytek Biosciences. His status as an executive officer makes him subject to ongoing SEC insider reporting requirements for ownership and certain transactions in Cytek securities.

Why is Cytek Biosciences (CTKB) filing a Form 3 for its Chief Legal Officer?

Form 3 is filed when someone becomes an insider subject to SEC Section 16 reporting. For Cytek Biosciences, registering its Chief Legal Officer, Ilan Feuchtwang, on Form 3 formally starts his obligation to report future transactions and holdings in company securities.

Does the CTKB Form 3 include any option or derivative positions?

The disclosed data show no derivative positions for Cytek Biosciences’ Chief Legal Officer. The derivative summary is empty, and derivative transaction counts are zero, indicating no reported options, warrants, or other derivative securities in this particular Form 3 filing snapshot.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Feuchtwang Ilan

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CALIFORNIA 94538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/29/2026

3. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer, Secretary

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Ilan Feuchtwang	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)